BASF, the world’s largest chemicals group by sales, will cut half of the 700 jobs at its plant biotechnology business, slashing some early development projects in yield improvement and stress tolerance and all of its rice yield and corn fungal resistance projects.
BASF’s plant biotechnology unit is developing improved plant characteristics such as drought tolerability but relies on partners, the biggest being Monsanto, to bring finished seed products to market.
Alliances with such partners are not affected by the cutbacks, a spokeswoman said.
BASF, also the world’s third largest maker of farming pesticides, spends about 150 million euros ($165 million) per year on plant biotechnology research but has not disclosed sales or earnings figures for these activities.
A spokeswoman declined to comment on any cuts to annual budgets at the unit.
($1 = 0.9076 euros) (Reporting by Ludwig Burger; Editing by Maria Sheahan)
This equipment will significantly lower the site’s CO2 emissions, reduce flaring and save around 60 gigawatt hours (GWh) energy each year. Project kick-off is in February 2021, with completion planned for 2023.
The acquisition significantly strengthens and expands Grace’s existing pharma portfolio. Pharma & Consumer is the largest, fastest growing and most profitable subsegment within Grace’s Materials Technologies business.
Solvay says it has decided to organize its soda ash and derivatives business into a separate and fully controlled legal structure.